Cargando…

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus

There are currently three thrombopoietin receptor agonists (TPO-RAs) approved in Europe for treating patients with immune thrombocytopenia (ITP): romiplostim (Nplate®), eltrombopag (Revolade®), and avatrombopag (Doptelet®). However, comparative clinical data between these TPO-RAs are limited. Theref...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pulanić, Dražen, Bátorová, Angelika, Bodó, Imre, Červinek, Libor, Ionita, Ioana, Lissitchkov, Toshko, Melikyan, Anahit, Podolak-Dawidziak, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951167/ https://www.ncbi.nlm.nih.gov/pubmed/36826482 http://dx.doi.org/10.1007/s00277-023-05114-8

Ejemplares similares

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method
por: Cuker, Adam, et al.
Publicado: (2020)

Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia
por: Bastida, José María, et al.
Publicado: (2021)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations
por: Carpenedo, Monica, et al.
Publicado: (2021)

Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia
por: Garzon, Angelica Maria, et al.
Publicado: (2015)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists
por: Nilles, Kathy M., et al.
Publicado: (2019)

Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
por: Shin, Jiwon, et al.
Publicado: (2023)

Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A
por: Batorova, Angelika, et al.
Publicado: (2022)

Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
por: González-Porras, José R., et al.
Publicado: (2019)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
por: Pecci, Alessandro, et al.
Publicado: (2017)

Primary Immune Thrombocytopenia and Essential Thrombocythemia: So Different and yet Somehow Similar—Cases Series and a Review of the Literature
por: Sobas, Marta, et al.
Publicado: (2021)

Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever?
por: Roy, Sayak
Publicado: (2019)

Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review
por: Agarwal, Nikki, et al.
Publicado: (2021)

Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
por: Drillet, Gaëlle, et al.
Publicado: (2022)

Icaritin Provokes Serum Thrombopoietin and Downregulates Thrombopoietin/MPL of the Bone Marrow in a Mouse Model of Immune Thrombocytopenia
por: Zhang, Ke, et al.
Publicado: (2018)

P1666: EFFECT OF AGONISTS TO THROMBOPOIETIN RECEPTORS ON PLATELET GLYCOME OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Monzón Manzano, E., et al.
Publicado: (2022)

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
por: Rainone, Michael, et al.
Publicado: (2023)

Serum Thrombopoietin and cMpl Expression in Thrombocytopenia of Different Etiologies
por: Vianello, Fabrizio, et al.
Publicado: (2014)

Serum Thrombopoietin Levels and Its Relationship With Thrombocytopenia in Patients With Cirrhosis
por: Temel, Tuncer, et al.
Publicado: (2014)

Thrombopoietin levels in Quebec platelet disorder—Implications for the mechanism of thrombocytopenia
por: Hayward, C. P. M., et al.
Publicado: (2018)

Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy
por: Zhang, Xu, et al.
Publicado: (2016)

Successful Treatment with Thrombopoietin Receptor Agonist in Avoiding Splenectomy for Patients with Chronic Refractory Immune Thrombocytopenia
por: Khalafallah, Alhossain, et al.
Publicado: (2012)

Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis
por: Guo, Jian-Chun, et al.
Publicado: (2017)

Thrombocytopenia and insufficient thrombopoietin production in human small-for-gestational-age infants
por: Takeshita, Satoru, et al.
Publicado: (2022)

Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag
por: Abdela, Jemal
Publicado: (2019)

PB2626: THROMBOPOIETIN RECEPTOR AGONISTS FOR RESISTANT THROMBOCYTOPENIA IN PREGNANCY A CASE SERIES AND REVIEW OF LITERATURE
por: Sayed, Gamal, et al.
Publicado: (2023)

Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis
por: Chen, Wen, et al.
Publicado: (2023)

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia
por: Janssens, Ann, et al.
Publicado: (2016)

Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report
por: Sobas, M. A., et al.
Publicado: (2017)

Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis
por: Wang, Li, et al.
Publicado: (2016)

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
por: Jurczak, Wojciech, et al.
Publicado: (2018)

Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
por: Lozano, Maria L., et al.
Publicado: (2019)

P1635: REAL-WORLD DATA OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) USE IN IMMUNE THROMBOCYTOPENIA (ITP)
por: Dangudubiyyam, S., et al.
Publicado: (2022)

PB2618: USE AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE CENTRE EXPERIENCE
por: Martinez, Celia, et al.
Publicado: (2023)

Expert consensus on the diagnosis and treatment of thrombocytopenia in adult critical care patients in China
por: Song, Jing-Chun, et al.
Publicado: (2020)

Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
por: Cai, Xuan, et al.
Publicado: (2022)

The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence
por: Qureshi, Kamran, et al.
Publicado: (2016)

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
por: Mei, Heng, et al.
Publicado: (2021)

Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report
por: Baur, Rebecca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_taan63medkisksktcrj7cr49hl